Table 2.
Laboratory values of ischemic stroke patients with malignancy (group 1) and those patients with no malignancy (group 2) at the time of presentation.
| Parameters | Group 1 (n = 91) | Group 2 (n = 87) | pa |
|---|---|---|---|
| BUN (mg/dl) | 25.19 ± 14.29 | 18.05 ± 7.01 | <0.001 |
| Cre (mg/dl) | 1.02 ± 0.47 | 0.90 ± 0.30 | 0.034 |
| AST (U/L) | (13–584) | (9–88) | 0.004 |
| ALT (U/L) | (6–236) | (6–71) | 0.001 |
| Hematocrit (%) | 36.24 ± 5.84 | 41.20 ± 5.20 | <0.001 |
| D.dimer (ug FEU/ml) | (0.10–11.55) | (0.10–8.70) | <0.001 |
| CRP (mg/dl) | (0.10–27.60) | (0.10–14.40) | <0.001 |
| Hemoglobin (g/dl) | 11.93 ± 1.98 | 13.61 ± 1.92 | <0.001 |
| Platelets (×103μL) | 262.58 ± 107.45 | 233.25 ± 66.35 | <0.001 |
Group 1, the ischemic stroke patients with malignancy (trousseau group); Group 2, the ischemic stroke patients with no malignancy. BUN, blood urine nitrogene; Cre, creatinine; AST, aspartate transaminase; ALT, alanine transaminase; CRP, c-reactive protein.
a
Student's t-test.